OCUL Jan 2025 4.500 call
| Previous close | 2.1000 |
| Open | 2.1000 |
| Bid | 0.7000 |
| Ask | 5.0000 |
| Strike | 4.50 |
| Expiry date | 2025-01-17 |
| Day's range | 2.1000 - 2.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 215 |
Simply Wall St.An Intrinsic Calculation For Ocular Therapeutix, Inc. (NASDAQ:OCUL) Suggests It's 45% Undervalued
Key Insights The projected fair value for Ocular Therapeutix is US$9.56 based on 2 Stage Free Cash Flow to Equity...
GlobeNewswireOcular Therapeutix® to Host Investor Day on June 13, 2024
Company to highlight corporate strategy, clinical data, and development plans for AXPAXLI™ in wet AMD and NPDR Event to feature prominent retinal disease experts Baruch D. Kuppermann, MD, PhD (University of California, Irvine) and Dilsher S. Dhoot, MD (California Retina Consultants) In-person event with virtual access to take place on June 13, 2024, at 2:00 PM ET BEDFORD, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical
- GlobeNewswire
Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that it has agreed to grant inducement awards to (i) its newly appointed Chief Medical Officer, Nadia K. W
